Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parathyroid hormone for prevention of refracture after osteoporotic vertebroplasty
ChiCTR1800016971Phase 4Recruiting
- Sponsor
- Shenzhen Nanshan People's Hospital
- Start
- Jul 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of parathyroid hormone 1-84 in osteoporotic vertebral fracture (OVF) and osteoporosis (2 arms), sponsored by Shenzhen Nanshan People's Hospital. Primary endpoint: Re-fracture rate. Started Jul 2018; status: recruiting.
02
Drugs
parathyroid hormone 1-84
03
Conditions
osteoporotic vertebral fracture (OVF)osteoporosis
Beyond the preview
Go deeper on ChiCTR1800016971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016971.